Cargando…

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors

Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. This review summarizes the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Javle, Milind, King, Gentry, Spencer, Kristen, Borad, Mitesh J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Hepatobiliary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628593/ https://www.ncbi.nlm.nih.gov/pubmed/37390492 http://dx.doi.org/10.1093/oncolo/oyad149

Ejemplares similares

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
por: Saridogan, Turcin, et al.
Publicado: (2023)

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
por: Kommalapati, Anuhya, et al.
Publicado: (2021)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
por: Bahleda, R., et al.
Publicado: (2020)

Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017
por: Javle, Milind, et al.
Publicado: (2022)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma
por: Jia, Xiuqin, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
por: Formisano, Luigi, et al.
Publicado: (2019)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
por: Zhou, Zhen, et al.
Publicado: (2021)

Aberrations in FGFR1, FGFR2, and RIP5 Expression in Human Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
por: Kelam, Nela, et al.
Publicado: (2022)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Association of Tumor Cell Metabolic Subtype and Immune Response With the Clinical Course of Hepatocellular Carcinoma
por: Wei, Xiaolin, et al.
Publicado: (2023)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Real-time virtual sonography-assisted radiofrequency ablation in liver tumors with conspicuous or inconspicuous images or peritumoral landmarks under ultrasonography
por: Huang, Hsin-Chih, et al.
Publicado: (2021)

Exploring the efficacy of (18)F-FDG PET/CT in hepatocellular carcinoma diagnosis: role of Ki-67 index and tumor differentiation
por: Yin, Yuping, et al.
Publicado: (2023)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
por: Klink, Andrew J, et al.
Publicado: (2022)

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
por: Jachs, Mathias, et al.
Publicado: (2023)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features
por: Liu, Jun, et al.
Publicado: (2021)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
por: Yu, Youxi, et al.
Publicado: (2021)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_npv2r3fehhnrj4hmbo4mmdpv6i